Based on our previous study of the combination of sorafenib with 5-azacytidine (AZA) in relapsed/ refractory patients with FLT3 mutated acute myeloid leukemia (AML), we hypothesized that the combination would be efficacious and well tolerated in untreated patients with FLT3 mutated AML who are unsuitable for standard chemotherapy due to advanced age or lack of fitness. Newly diagnosed patients with untreated FLT3 mutated AML who underwent frontline therapy on 2 separate protocols of AZA plus sorafenib were analyzed. The clinical trials were registered at clinicaltrials. The median duration of CR/CRp/CRi is 14.5 months (1.1-28.7 months). Three (11%) responding patients (1 CR, 2 CRi) proceeded to allogeneic stem cell transplant. The median follow-up for surviving patients was 4.1 months (3.0-17.3 months). The median overall survival for the entire group was 8.3 months, and 9.2 months in the 19 responders. The regimen was well tolerated in elderly patients with untreated FLT3 mutated AML with no early deaths.
| INTRODUCTION
We have previously reported that the combination of sorafenib with 5-azacytidine (AZA) is safe and effective in patients with relapsed and/or refractory FLT3-ITD mutated acute myeloid leukemia (AML). 1 Thus, we hypothesized that this combination would be efficacious and well tolerated in untreated patients with AML who are not suitable for standard intense chemotherapy due to advanced age or lack of fitness.
Newly diagnosed patients with untreated FLT3 mutated AML who underwent frontline therapy on 2 separate protocols of AZA plus sorafenib were included in this analysis. The clinical trials were registered at clinicaltrials.gov as NCT02196857 and NCT01254890.
| METHODS

| Patient selection
Newly diagnosed patients with AML on the Phase II portion of the Phase I/II study NCT01254890 and the Phase II NCT02196857 were treated with the regimen of AZA and sorafenib. The patients from the first trial have been reported on previously. 1 Patients were eligible for participation in the analysis if they had the FLT3-ITD mutation, age ≥ 60 years, ECOG performance status ≤ 2, and adequate organ function. Although the Phase II NCT02196857 trial allowed enrollment of patients younger than 60 years if they were unsuitable for standard cytotoxic chemotherapy, all patients treated were at least 60 years of age. The presence of the FLT3-ITD mutation was not a necessary inclusion criteria on the NCT01254890; however, the NCT02196857 required ≥ 10% FLT3-ITD burden.
Both studies required adequate hepatic function (serum total bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine aminotransferase and aspartate aminotransferase ≤ 2.5 × ULN and renal function (serum creatinine ≤ 1.5 × ULN). Both studies had the following exclusion criteria: malignant disease of the central nervous system, uncontrolled, hypertension, known history of congestive heart failure > NYHA class II, or advanced malignant hepatic tumors. The studies were approved by the University of Texas -MD Anderson Cancer
Center Institutional Review Board, and all participating patients signed an informed consent document in accordance with the Declaration of Helsinki.
| Treatment regimen
The regimen included AZA 75 mg/m 2 daily × 7 days and sorafenib 400 mg twice daily as previously published. 1 Cycles were repeated at approximately 1 month intervals until disease progression or development of intolerable toxicity that precluded continuation on the treatment. Dose adjustments for both sorafenib and azacytidine were allowed based on tolerability and presence of adverse events (AEs).
| Laboratory correlative studies
Peripheral blood (PB) samples for plasma inhibitory assay (PIA) and FLT3 ligand (FL) levels were performed at the laboratory of Dr Mark
Levis at Johns Hopkins University Medical Center. In vivo FLT3 inhibition was assessed using a surrogate ex vivo assay, the PIA assay, as previously described in. 
| Response criteria
Complete response (CR) was defined as per revised working group criteria 4 by ≤ 5% blasts in the bone marrow (BM) with PB demonstrat- 
| RESULTS
Overall, 27 patients with untreated AML (median age of 74 years;
range, 61-86 years) were enrolled. The clinical characteristics of the patients are described in Table 1 . A total of 17 (63%) patients had a normal karyotype, 2 (7%) had a complex karyotype, 4 (15%) had other miscellaneous abnormalities, and 4 (15%) had insufficient metaphases for analysis (Supporting Information Table S1 ). In addition to FLT3-ITD mutations being present in 100% of patients, 41% (n = 11) had NPM1 mutations, 22% (n = 6) had DNMT3A mutations, and 19% (n = 5) had IDH2 mutations. Other molecular mutations that were noted are shown in Supporting Information Table S1 . Prior to the initiation of treatment, FLT3-ITD was detected in all patients with a median allelic ratio of 0.379 (range, 0.009-0.65).
| Elderly patients receiving AZA combined with sorafenib experienced favorable response rates
The overall response rate in the 27 evaluable patients was 78% Three patients stayed on this treatment even after relapsing and maintained disease control over an additional median period of 4 months after relapse (range, 2-12 months); thus, the maximum number of cycles received on study exceeded the maximal remission (Figure 2A ). The median relapse-free survival duration, which was censored for loss of response/relapse and death while in CR, was 7.1 months (range, 1-29 months) ( Figure 2B ). There was no significant difference in FLT3-ITD burden between responders and nonresponders (P = .525).
| AZA combined with sorafenib was well tolerated
Overall, the majority of AEs reported during the study were grade 1 or grade 2, as described in Figure 3 . The most common grade 1/grade 2 AEs were hyperbilirubinemia (22%), diarrhea (22%), fatigue (22%), and nausea (19%). Among the grade 3/grade 4 AEs, infections (26%) and neutropenic fever (26%) were the most common (Figure 3 ).
There were no early deaths within 14 days of the study. 
| Correlative data confirmed inhibition of FLT3 phosphorylation
Plasma from the indicated study days (Supporting Information Figure S1 ) from 3 evaluable subjects who volunteered for correlative studies was used in the plasma inhibitory activity assay for FLT3, as described previously. 1-28.7) . B, The median relapse-free survival, which censored for loss of response/relapse and death in CR, was 7.1 months (1-29) [Color figure can be viewed at wieyonlinelibrary.com] underwent testing for %P-FLT3 at 2 time points; the first patient had inhibition of P-FLT3 by 97% (on day 7), and the second patient by 90% (on day 28). Although the third patient showed P-FLT3 inhibition by 98% on day 7 and 100% on day 28, he did not achieve a CR.
| DISCUSSION
Older patients with FLT3-ITD-mutated AML have a worse outcome than those with wild-type FLT3. In patients older than 60 years of age with normal-karyotype AML who received standard front-line induction therapy on CALGB protocols, those with FLT3-ITD mutations had similar complete remission rates (P = .64) but shorter disease-free survival (P = .007) and OS (P < .001). 5 When sorafenib was combined with 7 + 3 in patients ≥ 60 years of age, the observed 1-year OS was 62% (95% CI, 45%-78%) for the FLT3-ITD-mutated patients compared with 30% for a historical control group (P = .0001). 6 Progress has been slow in improving outcomes for elderly patients with AML, particularly for elderly patients harboring FLT3-ITD mutations. Serve et al. 7 previously reported no advantage over placebo when sorafenib was combined with daunorubicin and cytarabine in elderly patients with both mutated and wild-type FLT3.
Higher rates of treatment-related mortality and lower CR rates occurred in the sorafenib arm. AEs events, particularly infections, were more common in the sorafenib arm. Furthermore, sorafenib was discontinued due to toxicity or patient refusal more often than the placebo. 7 In contrast, the regimen of AZA plus sorafenib was well tolerated, with good patient compliance, and rarely required treatment interruptions or dose reductions. These observations and the fact that many elderly patients are not candidates for standard induction therapy suggest the need for less intensive yet effective regimens such as those combining target-specific drugs with epigenetic agents.
Given the significant toxicity observed in elderly patients receiving sorafenib in combination with standard chemotherapy reported by Serve et al., 7 lower-intensity combinations with sorafenib have been greatly needed, yet previous attempts to utilize sorafenib in combination with low-intensity therapy for elderly, unfit AML patients have been disappointing. For example, when sorafenib was combined with low-dose cytarabine in elderly patients with untreated high-risk MDS and AML (n = 21), an overall response rate of only 11.8% was observed. 8 In contrast, our study, with an overall response rate of rationale for the combination of AZA and sorafenib, 16 One possible explanation for this is that in contrast to decitabine being solely Based on the encouraging findings observed with AZA plus sorafenib in unfit, elderly FLT3-ITD-mutated patients with AML, larger randomized studies are required to fully understand the potential benefit of this regimen in the elderly. While longer follow-up and larger patient numbers are needed to better understand whether AZA plus sorafenib could improve survival, the safety and tolerability of this regimen, with no early deaths in our study, offer the opportunity to combine other targeted agents that are currently benefiting elderly patients with AML (eg, venetoclax) 22 with this regimen to further enhance its benefits.
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